Overview

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Miracogen Inc.